Article

FDA Briefs - March 1, 2002

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.